Navigation Links
RMi Introduces SyntheSight™ Pharma Multi-Channel Optimization Suite
Date:1/4/2012

DES MOINES, Iowa, Jan. 4, 2012 /PRNewswire/ -- Pharmaceutical marketers who need to calibrate multi-channel marketing and sales resources and spending to maximize ROI have limitless questions. SyntheSight™, a new proprietary pharmaceutical multi-channel marketing optimization methodology developed by RMi with a patent-pending IntelliScore™, provides actionable insights and ad hoc reporting to help brand leaders find answers.

SyntheSight features two primary components: OptiView™, an online dashboard environment, provides an action-oriented view of program performance and recommendations to optimize results; and IntelliScore features a real-time customer interaction quotient reflecting engagement and facilitating investment optimization for ROI.

"The pharmaceutical industry is struggling with accountability of multi-channel marketing spending and reliably predicting and measuring ROI," said Andrea Westmeyer, RMi president. "SyntheSight methodology allows our clients to carefully calibrate their brand marketing and sales functions based on real measurable marketing insights, and to better leverage that knowledge for increased brand sales, or throughout their enterprise or franchise."

RMi client Jay Appel, director of physician relationship marketing at Amgen, has had SyntheSight in test use for over one year. "This is the future of our business," he said. "From first impression to engagement to behavioral change, the SyntheSight methodology enables us to effectively evaluate key tactics as we optimize our multi-channel marketing."

According to Westmeyer, SyntheSight users engaged in multi-channel marketing programs have 51 percent greater physician engagement than programs utilizing sales alone. By month six of a SyntheSight –managed, multi-channel marketing program, 62 percent of targets were engaged with one or more program elements. On average, multi-channel marketing programs utilizing SyntheSight have produced an 11.8 percent sales lift for RMi clients, she noted.

Westmeyer said SyntheSight methodology offers marketers a real-time view of their customers to drive sales for a single brand, or to better leverage data insights to benefit multiple brands in an enterprise. According to Westmeyer, RMi's clients are using SyntheSight to fill the "actionable insights knowledge gaps" in their marketing organizations to help answer questions, such as:

  • Was marketing spend optimized? (Right target, message, choice of tactics? Positive ROI?)
  • What was the sales lift from marketing spend? Which tactics worked best?
  • Can I predict or forecast lost sales?
  • Can we leverage category insights into successful physician engagement from one brand to another?

"Breaking barriers to physician engagement requires cutting through the clutter with marketing and sales programs carefully calibrated to optimize sales growth, while controlling costs," Westmeyer concluded. "SyntheSight methodology in practice produces real. measurable. insight.™ which offers scalable solutions for any brand, franchise or enterprise marketing to HCPs."

About RMi

RMi is a peerless team of HCP marketing engagement specialists who break barriers, clutter and records with best-of-breed measurement and optimization strategies and technology to engage targets and increase sales. SyntheSight™, RMi's proprietary pharmaceutical industry multichannel optimization methodology, provides nearly real-time actionable insights to optimize sales and marketing spend. To learn more visit http://sales.rmarketing.com for a short video and capabilities overview.

CONTACT:

John Dutcher, APR, Dutcher & Associates, L.L.C.

515/334-3464; dna@qwestoffice.net

Or

Andrea Westmeyer, RMi

917/749-6875; awestmeyer@Rmarketing.com

 

™ SyntheSight, OptiView and IntelliScore are registered trademarks of RMi.

™ real. measurable. insight. is a registered trademark of RMi.


'/>"/>
SOURCE RMi
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
2. Dr. Dello Russo Introduces the New EYE-Q Lasik
3. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
4. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
5. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
6. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
7. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
8. Siemens Introduces New Standard of Care for Breast Ultrasound
9. Perceptive Informatics Introduces Medical Imaging Methodology to Accelerate Development Decisions About Alzheimers Treatments
10. Quest Diagnostics Introduces First Commercial Laboratory Test for Identifying the H1N1 Swine Flu Virus
11. VivoMetrics(R) Introduces Next Generation LifeShirt Prototype, a Smart Garment That Delivers Real-time Vital Signs Remotely to Healthcare Providers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... 6, 2016 Eurofins Genomics today announced ... College of American Pathologists (CAP) and certification under ... new laboratory in Louisville, KY ... American headquarters. "Our new CLIA-licensed and ... is still considered the ,Gold Standard, method for ...
(Date:12/6/2016)... Dec. 6, 2016 Two new disaster drones ... a simulated mass casualty event Tuesday at John Bell ... technology debuted before an audience including Mississippi ... from Homeland Security, Federal Law Enforcement Agencies, and the ... as HiRO (Health Integrated Rescue Operations), was developed by ...
(Date:12/6/2016)... 6, 2016  Arcturus Therapeutics, Inc. ("Arcturus" or ... today that it entered into collaboration with Takeda ... the treatment of NASH and other gastrointestinal (GI) ... LUNAR™ and UNA Oligomer chemistry. The financial terms ... commitment to and expertise in GI disorders, we ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... , ... “Tomorrow Trump Goes To Washington”: a brief but engaging illustration ... to America. “Tomorrow Trump Goes To Washington” is the creation of published author, Nancy ... country. , Nancy attributes her patriotic nature to her WWII veteran father. She ...
(Date:12/7/2016)... ... 2016 , ... Dr. Greg Leyer, the Chief Scientific Officer ... DC workshop on November 2nd. The conference was an opportunity for both probiotic ... regulations. , Dr. Leyer spoke about two main topics at the IPA ...
(Date:12/6/2016)... ... December 06, 2016 , ... Men with gum disease ... of serious health problems, such as cardiovascular illness, according to research cited in ... Hills Periodontics & Dental Implant Center notes that the correlation between periodontal disease ...
(Date:12/6/2016)... TX (PRWEB) , ... December ... ... in predictive and prescriptive health insights for population health management, announces today ... provider. VitreosHealth will leverage CitiusTech’s cloud-hosted clinical rules engine that offers advanced ...
(Date:12/6/2016)... ON (PRWEB) , ... December 06, 2016 , ... CarriersEdge, ... today announced a new suite of Driver Wellness courses. Offered in three modules, the ... a starting point so fleets can educate drivers about how to stay healthy on ...
Breaking Medicine News(10 mins):